A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate

Trial Profile

A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Apalutamide (Primary) ; Docetaxel (Primary) ; Leuprorelin; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 19 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 30 Jun 2017.
    • 05 Apr 2017 Planned initiation date changed from 26 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top